These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21446935)

  • 1. An analysis of world media reporting of two recent large randomized prospective trials investigating screening for prostate cancer.
    Lawrentschuk N; Daljeet N; Trottier G; Crawley P; Fleshner NE
    BJU Int; 2011 Oct; 108(8 Pt 2):E190-5. PubMed ID: 21446935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for prostate cancer: the current evidence and guidelines controversy.
    Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R
    Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies.
    Ilic D
    Recent Results Cancer Res; 2014; 202():65-71. PubMed ID: 24531779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERSPC, PLCO studies and critique of cochrane review 2013.
    Schröder FH
    Recent Results Cancer Res; 2014; 202():59-63. PubMed ID: 24531778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSA screening: determinants of primary-care physician practice patterns.
    Tasian GE; Cooperberg MR; Potter MB; Cowan JE; Greene KL; Carroll PR; Chan JM
    Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):189-94. PubMed ID: 22343837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer: to screen or not to screen.
    Bailey SJ; Brewster SF
    Arch Esp Urol; 2011 Jun; 64(5):406-18. PubMed ID: 21705812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians.
    Kell JS
    Can J Urol; 2010 Feb; 17 Suppl 1():18-25. PubMed ID: 20170597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Haines IE; Gabor Miklos GL
    J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners.
    Van der Meer S; Kollen BJ; Hirdes WH; Steffens MG; Hoekstra-Weebers JE; Nijman RM; Blanker MH
    BJU Int; 2013 Jul; 112(1):26-31. PubMed ID: 23465178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Screening for prostate cancer: an up date].
    Ito K
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):33-7. PubMed ID: 22241351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF; Andriole GL; Kramer BS; Hayes RB; Prorok PC; Gohagan JK;
    J Urol; 2005 Mar; 173(3):746-50; discussion 750-1. PubMed ID: 15711261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Portrayal of complementary and alternative medicine for cancer by top online news sites.
    Price A; Grann VR
    J Altern Complement Med; 2012 May; 18(5):487-93. PubMed ID: 22551076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Landmarks in prostate cancer screening.
    Schröder FH
    BJU Int; 2012 Oct; 110 Suppl 1():3-7. PubMed ID: 23046034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis of cancer of the prostate (I): Advancements in knowledge and practice since the consensus conference of 1989. The "Cancer of the Prostate" subcommittee of the Committee of Oncology of the French Association of Urology].
    Villers A; Grosclaude P; Haillot O; Abbou CC; Richard F; Boccon-Gibod L
    Prog Urol; 1997 Jun; 7(3):508-15. PubMed ID: 9273082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
    Bangma CH; van Schaik RH; Blijenberg BG; Roobol MJ; Lilja H; Stenman UH
    Eur J Cancer; 2010 Nov; 46(17):3109-19. PubMed ID: 21047594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
    Roobol MJ; van der Cruijsen IW; Schröder FH
    Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.